Square Wave and Differential Pulse Voltammetric Determination of Meloxicam in Pharmaceutical Formulations

Yıl 2022, Cilt: 2 Sayı: 1, 1 - 10, 25.01.2022

Fatma Demirkaya Miloğlu

Öz

Two new voltammetric methods (square wave (SWV) and differential pulse (DPV)) were developed and validated for the direct determination of meloxicam (MX) in pharmaceutical formulations (PFs) without any pre-processes steps. The anodic peaks were obtained in buffer (pH 4.85) on glassy carbon electrode (GCE). The both voltammetric methods were linear at concentration range of 10-90 µg/mL in PF. The validation of methods for MX in PF were determined by establishing specificity, linearity, sensitivity, precision, accuracy, recovery and ruggedness. The recovery results of MX in PFs were found as % 98.5 for SWV and % 98.7 for DPV, respectively. The both developed voltammetric methods were successfully applied for the determination of MX in PFs named Melox, Melcam and Zeloxim. The endogenous substances found in PF were not create electroactive interferences for determine MX. The obtained analysis results of the PFs containing MX by voltammetric methods were compared by using the student t-test with the claimed values and no found statistically differences. It is claimed that new voltammetric methods can be used routinely MX analysis in PFs.

Anahtar Kelimeler

Differential pulse voltammetry, meloxicam, pharmaceutical, square wave voltammetry

Kaynakça

• 1. Phillips WJ, Currier BL, Analgesic pharmacology: II. Specific analgesics. JAAOSJournal of the American Academy of Orthopaedic Surgeons. 2004; 12; 221-233.
• 2. Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, et al, Management of gout: a systematic review in support of an American College of Physicians clinical practice guideline. Annals of internal medicine. 2017; 166; 37- 51.
• 3. Soh J-W, Weinstein IB, Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Progress in experimental tumor research. 2003; 37; 261-283.
• 4. Pojarani LB, Zarifiazar S, Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMU Journal of Pharmaceutical Sciences. 2020; 3; 194-204.
• 5. Zawilla N, Mohammad MA-A, Aly SE-M, Determination of meloxicam in bulk and pharmaceutical formulations. Journal of pharmaceutical and biomedical analysis. 2003; 32; 1135-1144.
• 6. Garcia MS, Sánchez-Pedreño C, Albero MI, Marti J, Spectrophotometric methods for determining meloxicam in pharmaceuticals using batch and flow-injection procedures. European journal of pharmaceutical sciences. 2000; 9; 311-316.
• 7. Taha EA, Salama NN, Fattah LE-SA, Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1, 3-diazole (NBD-Cl). Chemical and pharmaceutical bulletin. 2006; 54; 653-658.
• 8. Bebawy LI, Stability-indicating method for the determination of meloxicam and tetracaine hydrochloride in the presence of their degradation products. Spectroscopy letters. 1998; 31; 797-820.
• 9. Hassan EM, Spectrophotometric and fluorimetric methods for the determination of meloxicam in dosage forms. Journal of pharmaceutical and biomedical analysis. 2002; 27; 771-777.
• 10. Taha EA, Salama NN, Abdel Fattah LS, Abdel Fattah, Stability-indicating methods for determination of meloxicam and tenoxicam in the presence of their degradation products. Spectroscopy letters. 2002; 35; 501-516.
• 11. Nemutlu E, Kir S, Method development and validation for the analysis of meloxicam in tablets by CZE. Journal of pharmaceutical and biomedical analysis. 2003; 31; 393-400.
• 12. Vignaduzzo SE, Castellano PM, Kaufman TS, Method development and validation for the simultaneous determination of meloxicam and pridinol mesylate using RP-HPLC and its application in drug formulations. Journal of pharmaceutical and biomedical analysis. 2008; 46; 219-225.
• 13. Madni A, Ahmad M, Usman M, Zubair MM, Shoiab H, Khan S, et al, New high performance liquid chromatographic method for simultaneous determination of diclofenac and meloxicam in oral formulation of liposomes and human plasma. Journal of the chemical society of Pakistan. 2010; 32; 654-661.
• 14. Altınöz S, Nemutlu E, Kır S, Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma. Il Farmaco. 2002; 57; 463- 468.
• 15. Altiokka G, Atkosar Z, Tuncel M, Pulse polarographic determination of meloxicam. Pharmazie. 2001; 56; 184-185.
• 16. Radi A-E, Ghoneim M, Beltagi A, Cathodic adsorptive stripping square-wave voltammetry of the anti-inflammatory drug meloxicam. Chemical and pharmaceutical bulletin. 2001; 49; 1257-1260.
• 17. Beltagi A, Ghoneim M, Radi A, Electrochemical reduction of meloxicam at mercury electrode and its determination in tablets. Journal of pharmaceutical and biomedical analysis. 2002; 27; 795-801.
• 18. Radi A, El Ries M, El-Anwar F, El-Sherif Z, Electrochemical oxidation of meloxicam and its determination in tablet dosage form. Analytical letters. 2001; 34; 739-748.
• 19. Laviron E, Roullier L, Degrand C, A multilayer model for the study of space distributed redox modified electrodes: Part II. Theory and application of linear potential sweep voltammetry for a simple reaction. Journal of Electroanalytical Chemistry and Interfacial Electrochemistry. 1980; 112; 11-23.
• 20. Walfish S, Analytical methods: a statistical perspective on the ICH Q2A and Q2B guidelines for validation of analytical methods. BioPharm International. 2006; 19; 1-6.
• 21. El-Hefnawey G, El-Hallag I, Ghoneim E, Ghoneim M, Voltammetric behavior and quantification of the sedative-hypnotic drug chlordiazepoxide in bulk form, pharmaceutical formulation and human serum at a mercury electrode. Journal of pharmaceutical and biomedical analysis. 2004; 34; 75-86.